Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Exome sequencing of Emory and CFW mice

PROVIDER: PRJNA852584 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19846987_1.fastq.gz	Fastqsanger.gz
	SRR19846987_2.fastq.gz	Fastqsanger.gz
	SRR19846988_1.fastq.gz	Fastqsanger.gz
	SRR19846988_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Acquisition of additional mutations drives accelerated progression of NPM1 positive mice to AML Part II

Project description:We performed exome sequencing on samples from mice with accute myeloid leukeamia (AML). These mice were already sensitised to developing AML by the presence of mutations known to be key in the AML genesis. Exome sequencing was used to identify co-operating mutations in single and double mutant sensitised mice. Here we are performing re-sequencing of the putative driver and some passenger mutations which appear to be in the same clone to validate these mutations and to verify the relative quantification of these abnormalities .This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2015-09-08 | E-ERAD-393 | biostudies-arrayexpress

Project description:Carworth Farms White (CFW) outbred mice, 30x whole genome sequencing

| PRJNA1229615 | ENA

Next Generation Sequencing Analysis of Mice Glioma Exomes

Project description:Six samples from two Glioma_CKO mice (one normal brain tissue, two tumor tissues per mouse) were performed Whole Exome Sequencing

2022-01-11 | GSE160659 | GEO

Cancer Health Assessments Reaching Many

Project description:The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population includes adults at risk for hereditary cancer syndromes. The primary objective is to implement a hereditary cancer risk assessment program in healthy 18-49 year-olds in primary care settings within a vertically integrated health delivery system (Kaiser Permanente) and a federal qualified health center (Denver Health). The investigators will assess clinical exome sequencing implementation and interpretation, as well as tailored interactions for low health literacy including a contextualized consent process, and a modified approach to results disclosure and genetic counseling. The investigators will also assess the clinical utility (healthcare utilization and adherence to recommended care) and personal utility of primary and additional results from clinical exome sequencing, and evaluate the ethical and policy implications of considering personal utility of genomic information decisions for health care coverage.

| 2265388 | ecrin-mdr-crc

Chondrosarcoma Validation Study

Project description:Agilent whole exome hybridisation capture was performed on genomic DNA derived from Chondrosarcoma cancer and matched normal DNA from the same patients. Next Generation sequencing performed on the resulting exome libraries and mapped to build 37 of the human reference genome to facilitate the identification of novel cancer genes. Now we aim to re find and validate the findings of those exome libraries using bespoke pulldown methods and sequencing the products.

2016-05-17 | E-ERAD-37 | biostudies-arrayexpress

Leukemias from NP23-NHD13 double transgenic mice - WES study

Project description:Whole exome sequencing (the SureSelectXT Mouse All Exon Kit) was done on leukemias from NP23-NHD13 double transgenic mice with strain background designated “C57Bl6-NIH”.

2020-09-10 | GSE137542 | GEO

Project description:Carworth Farms White (CFW) outbred mice, low-coverage whole genome sequencing

| PRJNA1230210 | ENA

PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age related clonal hematopoiesis and myeloid neoplasia

Project description:Whole exome sequencing of 5 MDS/MPN patients to identify the target of chromosome 22 acquired uniparental disomy (22aUPD). For samples E4051 and E6523, peripheral blood leucocytes (tumour) and cultured T-cells (germline) were prepared for exome sequencing using the Agilent SureSelect kit (Agilent Technologies, Palo Alto, CA, USA) (Human All Exon 50 Mb) and then sequenced on an Illumina HiSeq 2000 (Illumina, Great Abington, UK) at the Wellcome Trust Centre for Human Genetics, Oxford, UK. For samples ULSAM1182, ULSAM1242 and ULSAM1356, peripheral blood leukocyte DNA only were exome sequenced by SciLifeLab (Stockholm, Sweden).

2019-01-22 | E-MTAB-7491 | biostudies-arrayexpress

Heterogeneous immune and tumor clonal evolution patterns in liver cancer

Project description:Paired end whole exome sequencing for patient 10, matched normal and tumor

2020-02-01 | E-MTAB-8127 | biostudies-arrayexpress

A founder heterozygous MBD4 mutation prevalent among Israeli Christian Arabs predisposes to somatic mutagenesis

Project description:whole exome sequencing analysis of donors with heterozygous and homozygous germline mutation

2025-02-21 | E-MTAB-14787 | biostudies-arrayexpress